PHARMACOKINETIC INTERACTIONS BETWEEN CONCOMITANTLY ADMINISTERED PHENYTOIN WITH RIVAROXABAN

Authors

  • Y. Karnakar Reddy Mewar University, NH-79, Gangrar, Chhitorgarh-312901, Rajasthan, India
  • T. Ramamohan Reddy Mewar University, NH-79, Gangrar, Chhitorgarh-312901, Rajasthan, India

Abstract

In the present investigation it was aimed to evaluate any possible pharmacokinetic interactions between Phenytoin and Rivaroxaban. Study was conducted in Male Wistar rats; animals were divided into three groups. Group 1 received Phenytoin alone, Group 2 received Rivaroxaban alone and Group 3 received Phenytoin and Rivaroxaban concomitantly. The treatment was given for 8 days and the blood samples were collected on day 1 and day 8. The samples were analyzed by HPLC. The results were showed no significant difference in the Pharmacokinetic parameters of Phenytoin in presence of Rivaroxaban. Whereas Rivaroxaban showed significant decrease in both Cmax and tmax in combination with Phenytoin. Phenytoin is a combined-gp inducer and strong CYP3A4 inducer therefore it may induce the metabolism of Rivaroxaban so it reduces the concentrations and increase the elimination rate. Based on the results obtained from pharmacokinetic study it was evident that the single dose of Rivaroxaban in combination with Phenytoin shows statistically significant interactions in its pharmacokinetic parameters.

Keywords:

Phenytoin, Rivaroxaban, Anticoagulant, Pharmacokinetic interactions

DOI

https://doi.org/10.25004/IJPSDR.2018.100507

References

1. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. 2008; JAMA 300: 2867-2878.
2. Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Reviews. 2017; 31(1): 77–84.
3. Stollberger C, Finsterer J. Interactions between non- vitamin K oral anticoagulants and antiepileptic drugs. Epilepsy Research. 2016; 126: 98–101.
4. Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants, Annals of Pharmacotherapy. 2013; 47(11):1478–1487.
5. Patsalos PN. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002; 43: 365-89.
6. French JA, Gidal EB. Antiepileptic drug interaction. Epilepsia. 2000; 41(8): 30-6.
7. Bourgeois BF. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia. 1995; 36(5): 1-7.
8. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ. For the re-cover Study Group: Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361: 2342-2352.
9. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Vedel Christiansen A, Friedman J, Le Maulf F, Peter N, Kearon C. RE-COVER II Trial Investigators: Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014; 129: 764-772.

Published

01-09-2018
Statistics
Abstract Display: 336
PDF Downloads: 558
Dimension Badge

How to Cite

“PHARMACOKINETIC INTERACTIONS BETWEEN CONCOMITANTLY ADMINISTERED PHENYTOIN WITH RIVAROXABAN”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 10, no. 5, Sept. 2018, pp. 406-9, https://doi.org/10.25004/IJPSDR.2018.100507.

Issue

Volume 10, Issue 5, 2018

Section

Research Article

How to Cite

“PHARMACOKINETIC INTERACTIONS BETWEEN CONCOMITANTLY ADMINISTERED PHENYTOIN WITH RIVAROXABAN”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 10, no. 5, Sept. 2018, pp. 406-9, https://doi.org/10.25004/IJPSDR.2018.100507.